Global Fungal Disease Surveillance and Capacity

The summary for the Global Fungal Disease Surveillance and Capacity grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control NCEZID, which is the U.S. government agency offering this grant.
Global Fungal Disease Surveillance and Capacity: Fungal diseases pose a significant public health threat. Infections may be opportunistic, affecting those with weakened immune systems or living with HIV/AIDS, hospital or community acquired, and a growing number are multidrug-resistant. The outcome of this NOFO is to reduce illness and death due to fungal diseases and improve the clinical outcomes for patients with fungal disease. Some activities supporting this goal include monitoring trends in fungal disease burden, improving diagnostic capacity and treatment availability, and raising awareness among the public about the threat of fungal diseases. This NOFO addresses both known and emerging fungal pathogens. Strategies for this NOFO are four-fold: increase fungal surveillance by building epidemiology and laboratory capacity; support identification of known and emerging fungal pathogens for timely response; promote workforce development and provide training in the prevention and control of fungal diseases and increase awareness of fungal disease among the public; and monitor and evaluate the impact of these interventions and assess and refine performance metrics. These strategies are intended to promote health equity at the programmatic, infrastructural and policy levels. This NOFO recognizes that recipients may work to build the capacity to prevent and control specific fungal pathogens or may respond to emerging fungal pathogens or issues, such as antimicrobial resistance. As one of the only public health groups devoted to the prevention and control of fungal infections, MDB works with partners worldwide to understand who gets fungal infections, and why, by using epidemiologic, microbiologic, and bioinformatics approaches. MDB responds to emerging fungal threats, such as azole-resistant Aspergillus infections and COVID-19 associated aspergillosis. MDB partnered to identify and respond to an unknown pathogen in Pakistan in 2015, which turned out to be C. auris, a life-threatening, multidrug-resistant fungus that subsequently rapidly spread across the United States. MDB is responsive to emerging fungal needs across the globe. CDC's Containment Strategy keeps new or rare forms of antibiotic resistance from spreading. Containment complements foundational CDC strategies, including improving antibiotic use and preventing infections, and builds on existing detection and response structure. In Colombia, surveillance for Candida infection early in 2016 primed the country to rapidly detect and respond to invasive Candida auris later that year, and hospital surveillance sampling demonstrated transmission in health care settings. Histoplasmosis is a common fungal infection throughout much of Latin America in both immunocompromised and immunocompetent people. It rivals tuberculosis as a cause of death in people living with HIV in the region. However, it is widely underdiagnosed. CDC is partnering to improve access to diagnostic testing and treatment to reduce illness and death. Sporothrix brasiliensis is an emerging fungal pathogen in South America which CDC is responding to. Unlike its better-known relative, Sporothrix schenckii, which is found in the environment, S. brasiliensis causes zoonotic infections and can spread explosively between cats and from cats to humans. One Health approaches are likely to be effective in minimizing spread of S. brasiliensis. Death from cryptococcal meningitis in immunosuppressed people can be prevented with improved access to antifungal medications. Partnering with countries in sub-Saharan Africa, CDC has worked to improve sustainable access to these life-saving drugs and provide education to healthcare provider on their use, ultimately preventing deaths in people living with HIV/AIDS. MDB has provided technical assistance to research on development of antimicrobials for drug resistant pathogens, such as Candida auris.
Federal Grant Title: Global Fungal Disease Surveillance and Capacity
Federal Agency Name: Centers for Disease Control NCEZID (HHS-CDC-NCEZID)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: CDC-RFA-CK21-2106
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.318
CFDA Descriptions: Information not provided
Current Application Deadline: July 27th, 2021
Original Application Deadline: July 27th, 2021
Posted Date: May 27th, 2021
Creation Date: May 27th, 2021
Archive Date: August 26th, 2021
Total Program Funding: $2,500,000
Maximum Federal Grant Award: $300,000
Minimum Federal Grant Award: $25,000
Expected Number of Awards: 10
Cost Sharing or Matching: No
Last Updated: July 6th, 2021
Applicants Eligible for this Grant
Unrestricted (i.e., open to any type of entity below), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility
Consideration will be given to teaching hospitals associated with academic institutions, other global governmental entitites, and other organizations that demonstrate a history and capacity of global work, preferably experience conducting fungal activities globally. Individuals are not eligible for this opportunity.
Grant Announcement Contact
Lynette Benjamin
[email protected]
[email protected]
Similar Government Grants
Public Health Partnerships to Accelerate Prevention and Control of Infectious Diseases and...
Achieving Global Health Security Through Strengthening Public Health Emergency Preparednes...
Advancing Diagnostic Network Optimization, Stepwise Laboratory Accreditation, and Integrat...
Strengthening immunization program implementation in sub-national consequential geographie...
Public Health Systems Capacity Building in Central Asia
Improving the Capacity of Panel Physicians Performing Overseas Medical Examinations of U.S...
Protecting and Improving Public Health Globally: Building and Strengthening Public Health ...
More Grants from the Centers for Disease Control NCEZID
Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Dis...
Emerging Infections Program
CDC-Mexico Cooperative Agreement for Surveillance, Epidemiology, and Laboratory Capacity
Strengthening Global Capacity for Molecular Surveillance and Outbreak Response for Enteric...
Strengthening Training, Evaluation, and Partnerships in the Prevention and Control of Vect... is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024